Marvel BiosciencesMBCOF 34 Receivables Turnover is 0.00 as of Apr. 2026. GuruFocus rates MBCOF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 844 Biotechnology companies, Marvel Biosciences ranks worse than 118483.29% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Marvel Biosciences's Revenue for the
three
months ended in Apr. 2026 was $0.00 Mil. Marvel Biosciences's average Accounts Receivable for the
three
months ended in Apr. 2026 was $0.00 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Marvel Biosciences Receivables Turnover Related Terms
Marvel Biosciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Marvel Biosciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MBCOF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Marvel Biosciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marvel Biosciences Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Marvel Biosciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marvel Biosciences (MBCOF) has a Receivables Turnover of 0.00 as of Apr. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Marvel Biosciences and its competitors. According to the industry distribution chart, Marvel Biosciences ranks #999999 out of 844 companies in the Biotechnology industry.
Is Marvel Biosciences' Receivables Turnover too high?
Marvel Biosciences' current Receivables Turnover is 0.00. Based on the distribution chart, Marvel Biosciences ranks #999999 out of 844 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Marvel Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Marvel Biosciences' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marvel Biosciences ranks #999999 out of 844 companies for Receivables Turnover. This places Marvel Biosciences in the lower half of its industry. The industry median Receivables Turnover is 5.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 844 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Marvel Biosciences and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marvel Biosciences's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marvel Biosciences stock overvalued right now?
Marvel Biosciences (MBCOF) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Marvel Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Marvel Biosciences (MBCOF), the current Receivables Turnover is 0.00 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Marvel Biosciences Corp is a biotechnology company incorporated in Canada. The Company is currently a pre-clinical stage pharmaceutical development company that utilizes a drug redevelopment approach to identify and evaluate potential therapeutic compounds. Its activities mainly involve scientific research and pre-clinical studies aimed at determining viable active compounds for further drug development.
34GF Score
Get the complete analysis for MBCOF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBCOF has been successfully added to your 
